BlueRock Hires Former Unum Exec Ettenberg as Chief Scientific Officer

Xconomy Boston — 

BlueRock Therapeutics has appointed Seth Ettenberg to serve as its chief scientific officer. He comes to the Cambridge, MA-based cell and gene therapy developer from Unum Therapeutics (NASDAQ: UNUM), where he was chief scientific officer from the company’s 2014 founding until a corporate restructuring earlier this week. BlueRock, which was acquired by Bayer last year in a deal that values the biotech at $1 billion, is developing therapies for neurological, cardiovascular, and immune disorders.